| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910437613903321 |
|
|
Autore |
Aptsiauri Natalia |
|
|
Titolo |
MHC Class I Antigens In Malignant Cells : Immune Escape And Response To Immunotherapy / / by Natalia Aptsiauri, Angel Miguel Garcia-Lora, Teresa Cabrera |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
New York, NY : , : Springer New York : , : Imprint : Springer, , 2013 |
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Edizione |
[1st ed. 2013.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (51 p.) |
|
|
|
|
|
|
Collana |
|
SpringerBriefs in Cancer Research, , 2194-1181 ; ; 1 |
|
|
|
|
|
|
Altri autori (Persone) |
|
Garcia-LoraAngel Miguel |
CabreraTeresa |
|
|
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Cancer |
Immunology |
Medicine - Research |
Biology - Research |
Cancer Biology |
Biomedical Research |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Note generali |
|
Description based upon print version of record. |
|
|
|
|
|
|
Nota di contenuto |
|
Overview of MHC Class I Antigens -- HLA Class I Expression In Human Cancer -- MHC Class I Expression In Experimental Mouse Models Of Cancer: Immunotherapy Of Tumors With Different MHC-I Expression Patterns -- Potential Therapeutic Approaches For Increasing Tumor Immunogenicity By Upregulation Of Tumor HLA Class I Expression -- Conclusion. |
|
|
|
|
|
|
|
|
Sommario/riassunto |
|
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the |
|
|
|
|
|
|
|
|
|
|
prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. . |
|
|
|
|
|
| |